Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO)

被引：0
|
作者：
Chen, Inna Markovna
Johansen, Julia S.
Theile, Susann
Madsen, Kasper
Dajani, Olav
Lorentzen, Torben
Zimmers, Teresa
Nielsen, Dorte
机构：
[1] Copenhagen Univ Hosp Herlev & Gentofte, Herlev, Denmark
[2] Oslo Univ Hosp, Oslo, Norway
[3] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4147
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    Chen, I.
    Johansen, J. S.
    Zimmers, T. A.
    Dehlendorff, C.
    Parner, V. Kirk
    Jensen, B. Vittrup
    Nielsen, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [3] Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer
    Kokkali, S.
    Drizou, M.
    Tripodaki, E.
    Stefanou, D.
    Magou, E.
    Zylis, D.
    Kapiris, M.
    Nasi, D.
    Georganta, C.
    Ardavanis, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Neuger, Anthony
    Almhanna, Khaldoun
    Wapinsky, Georgine
    Bertels, Barbara
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [7] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [9] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [10] Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
    Sahai, Vaibhav
    Catalano, Paul J.
    Zalupski, Mark M.
    Lubner, Sam Joseph
    Menge, Mark R.
    Nimeiri, Halla Sayed
    Munshi, Hidayatullah G.
    Benson, Al Bowen, III
    O'Dwyer, Peter J.
    JAMA ONCOLOGY, 2018, 4 (12) : 1707 - 1712
12345